Olaparib

≥98% (HPLC), PARP-1, PARP-2 inhibitor, powder

Sinônimo(s):

1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine, 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone, AZD-2281, KU-0059436

Sobre este item

Fórmula empírica (Notação de Hill):

C₂₄H₂₃FN₄O₃

Número CAS:

763113-22-0

Peso molecular:

434.46

Número MDL:

MFCD13185161

Código UNSPSC:

12352200

NACRES:

NA.77

Nome do produto

Olaparib, ≥98% (HPLC)

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear (Warmed)

temperatura de armazenamento

-10 to -25°C

cadeia de caracteres SMILES

Fc1c(cc(cc1)C=C4NNC(=O)c5c4cccc5)C(=O)N2CCN(CC2)C(=O)C3CC3

InChI

1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13-14,16,26H,6-7,9-12H2,(H,27,30)

chave InChI

JQYIJKFTPJWNFM-UHFFFAOYSA-N

Ações bioquímicas/fisiológicas

Antineoplastic; Poly(ADP-ribose) polymerases-1 and 2 (PARP-1, PARP-2) inhibitor

Olaparib is an antineoplastic and potent inhibitor of poly(ADP-ribose) polymerases-1 and 2 (PARP-1, PARP-2) with an IC50 of 5 nM for PARP-1 and an IC50 of 1 nM for PARP-2. Olaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.